TY - JOUR
TI - FGFR3 expression in primary and metastatic urothelial carcinoma of the
bladder
AU - Guancial, Elizabeth A.
AU - Werner, Lillian
AU - Bellmunt, Joaquim and
AU - Bamias, Aristotle
AU - Choueiri, Toni K.
AU - Ross, Robert
AU - Schutz,
AU - Fabio A.
AU - Park, Rachel S.
AU - O'Brien, Robert J.
AU - Hirsch, Michelle
AU - S.
AU - Barletta, Justine A.
AU - Berman, David M.
AU - Lis, Rosina and
AU - Loda, Massimo
AU - Stack, Edward C.
AU - Garraway, Levi A.
AU - Riester,
AU - Markus
AU - Michor, Franziska
AU - Kantoff, Philip W.
AU - Rosenberg,
AU - Jonathan E.
JO - Cancer Medicine
PY - 2014
VL - 3
TODO - 4
SP - 835-844
PB - Wiley
SN - 2045-7634
TODO - 10.1002/cam4.262
TODO - Biomarker; bladder cancer; FGFR3; metastatic urothelial carcinoma;
muscle-invasive urothelial carcinoma; targeted therapy
TODO - While fibroblast growth factor receptor 3 (FGFR3) is frequently mutated
or overexpressed in nonmuscle-invasive urothelial carcinoma (UC), the
prevalence of FGFR3 protein expression and mutation remains unknown in
muscle-invasive disease. FGFR3 protein and mRNA expression, mutational
status, and copy number variation were retrospectively analyzed in 231
patients with formalin-fixed paraffin-embedded primary UCs, 33
metastases, and 14 paired primary and metastatic tumors using the
following methods: immunohistochemistry, NanoString nCounterTM, OncoMap
or Affymetrix OncoScanTM array, and Gain and Loss of Analysis of DNA and
Genomic Identification of Significant Targets in Cancer software. FGFR3
immunohistochemistry staining was present in 29% of primary UCs and
49% of metastases and did not impact overall survival (P = 0.89,
primary tumors; P = 0.78, metastases). FGFR3 mutations were observed in
2% of primary tumors and 9% of metastases. Mutant tumors expressed
higher levels of FGFR3 mRNA than wild-type tumors (P < 0.001). FGFR3
copy number gain and loss were rare events in primary and metastatic
tumors (0.8% each; 3.0% and 12.3%, respectively). FGFR3
immunohistochemistry staining is present in one third of primary
muscle-invasive UCs and half of metastases, while FGFR3 mutations and
copy number changes are relatively uncommon.
ER -